Lonza Group Ltd
LONN: XSWX (CHE)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|RK | LOCK|gPt@P | LOCK|L^T@JDC |
Lonza Earnings: Strong Demand For Outsourced Drug Manufacturing Supports Long-Term Growth
Lonza provided a first-quarter qualitative business update, reporting strong performance across its contract development and manufacturing organization business, in line with its 2026 outlook of 11%-12% sales growth at constant exchange rates and a core EBITDA margin above 32%.
